GlucoFriend-evaluation the Effectiveness of Glucobay When Combined With a Basal Insulin
This study has been completed.
Information provided by:
First received: November 24, 2010
Last updated: June 19, 2013
Last verified: June 2013
To evaluate the effectiveness of Glucobay when combined with a basal insulin under daily-life treatment conditions in a large sample of Korean patients.
|Study Design:||Time Perspective: Prospective|
|Official Title:||Combined Use of a Basal Insulin and Glucobay For Reducing PPG to End Diabetes Progress|
Resource links provided by NLM:
U.S. FDA Resources
Further study details as provided by Bayer:
Primary Outcome Measures:
- Change in HbA1c [ Time Frame: After 20 weeks ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Duration and dose of acarbose treatment [ Time Frame: After 20 weeks ] [ Designated as safety issue: No ]
- Postprandial Blood Glucose [ Time Frame: After 20 weeks ] [ Designated as safety issue: No ]
|Study Start Date:||September 2010|
|Study Completion Date:||July 2012|
Drug: Acarbose (Glucobay, BAYG5421)
Adult female and male patients are scheduled to be treated with acarbose will be enrolled after the therapy decision has been made. Physicians should consult the full prescribing information for Glucobay® before enrolling patients and familiarize themselves with the safety information in the product package label.
Contacts and Locations